24/7 Market News Snapshot 27 May, 2025 – Imunon, Inc. Common Stock (NASDAQ:IMNN)

May 27, 2025

DENVER, Colo., 27 May, 2025 (www.247marketnews.com) – (NASDAQ:IMNN) are discussed in this article.
Imunon, Inc. (IMNN) has reported a notable decrease in its stock price, currently trading at $1.006, down approximately 13.28% from its previous close of $1.160, at an opening price of $0.855. The heightened trading volume of 9.46 million shares indicates increased investor engagement, which may reflect market volatility. This decline could be a sign of profit-taking or cautious sentiment following recent gains. Investors are advised to monitor critical support levels around $0.855 and potential resistance near $1.160 to enhance their risk management strategies during this period of fluctuation.

In tandem with market activities, Imunon is making significant strides in its core therapeutic offerings, particularly with its investigational immunotherapy, IMNN-001. The company is set to present encouraging findings from the Phase 2 OVATION 2 Study at the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2025, scheduled for June 19-21. An oral presentation detailing an immune biomarker analysis from the study is also anticipated at the forthcoming American Society of Clinical Oncology (ASCO) Annual Meeting, underscoring the growing interest in IMNN-001.

This DNA-mediated immunotherapy utilizes proprietary TheraPlas® technology to deliver interleukin-12 (IL-12) via a nanoparticle system, aiming for sustained local secretion within the tumor microenvironment. Recent results demonstrate a significant median overall survival increase of 13 months and a three-month extension in progression-free survival among patients treated with IMNN-001.

Dr. Stacy Lindborg, President and CEO of Imunon, expressed enthusiasm about the positive reception from the scientific community and growing engagement from researchers eager to contribute to the upcoming Phase 3 OVATION 3 Study. This next phase is poised to further validate IMNN-001’s potential impact on the health outcomes of the estimated 40,000 women diagnosed with advanced ovarian cancer annually in Europe, along with over 300,000 globally. Imunon is dedicated to advancing therapies that leverage the body’s immune response, aiming for transformative improvements in cancer treatment.

Related news for (IMNN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.